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Abstract 
Biophysical screening techniques, such as surface plasmon resonance, enable detailed 
kinetic analysis of ligands binding to solubilised G-protein coupled receptors. The activity of a 
receptor solubilised out of the membrane is crucially dependent on the environment in which 
it is suspended. Finding the right conditions is challenging due to the number of variables to 
investigate in order to determine the optimum solubilisation buffer for any given receptor.  In 
this study we used surface plasmon resonance technology to screen a variety of solubilisation 
conditions including buffers and detergents for two model receptors: CXCR4 and CCR5. We 
tested 950 different combinations of solubilisation conditions for both receptors. The activity 
of both receptors was monitored by using conformation dependent monoclonal antibodies and 
the binding of small molecules ligands. Despite both receptors belonging to the chemokine 
receptor family they show some differences in their preference for solubilisation conditions 
that provide the highest level of binding for both the conformation dependent antibodies and 
small molecules. The study described here is focused not only on finding the best solubilisation 
conditions for each receptor, but also on factors that determine the sensitivity of the assay for 
each receptor.  We also suggest how these data about different buffers and detergents can 
be used as a guide for selecting solubilisation conditions for other membrane proteins. 
Keywords: GPCRs, Surface plasmon resonance, Solubilisation conditions, Detergents, 
Screening 
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Introduction 
G-protein coupled receptors (GPCRs) are the largest class of drug targets due to the size of 
the gene family in the human genome and the breadth of extracellular ligands members that 
GPCRs have evolved to respond to. GPCRs are integral membrane proteins containing seven 
transmembrane α-helices. The membrane-bound nature of GPCRs is a persistent challenge 
to the application of modern biophysical techniques routinely used in drug discovery. In recent 
years there have been advances in exploiting biophysical methods, such as X-ray protein 
crystallography and surface plasmon resonance, for screening GPCRs [1-3]. However, in 
order to carry out biophysical studies, recombinant GPCRs must first be isolated from the 
membrane with the hydrophobic transmembrane regions embedded in an appropriate 
environment. In order to facilitate their analysis two general strategies have been employed to 
stabilise them outside of their natural membrane environment. One set of strategies employs 
conformational stabilisation of the GPCRs by either mutagenesis to increase the 
thermostability of the protein [2-4] or by the formation of stable complexes [5] (e.g. with 
antibody fragments or nanobodies). These methods have proven successful for both 
crystallizing GPCRs for X-ray analysis and also for surface plasmon resonance (SPR). A 
second strategy, generally but not exclusively used in conjunction with the first strategy, is to 
stabilize the transmembrane region of the receptor outside of its native environment by using 
a membrane mimetic system. Membrane mimetic systems generally involve solubilisation of 
the receptor in detergents or in an artificial membrane [6-8]. The advantage of solubilisation 
techniques is that, unlike stabilisation through mutagenesis, where stability arises from locking 
the structures in one conformation, the full range of tertiary structure conformations and thus 
full pharmacological function remains. Solubilisation methods have proved particularly useful 
in enabling SPR to be applied to the study of fully functional, ‘wild type’ GPCRs for screening 
of antibodies, small molecule drugs and low molecular weight ‘fragment’ compounds (Mw < 
250 Da) [9-11]. Despite the potential for solubilisation strategies to expand the repertoire of 
GPCRs that can be studied by SPR screening, there has been relatively little systematic 
analysis of the landscape of detergent, lipid and buffer mixtures that result in active wildtype 
receptors being immobilised on a biosensor surface.   
To better understand the range of solubilisation conditions that are tolerated by active GPCRs, 
we undertook a large-scale screen of buffer and detergent solubilisation conditions using 
surface plasmon resonance based biosensors on two model receptors: CXCR4 and CCR5. 
Smaller scale detergent screens using SPR have been described previously [11, 12]. We have 
expanded upon previous work by extending the search space by testing 950 different 
combinations of solubilisation conditions for two receptors. Conformation dependent 
monoclonal antibodies specific to active properly folded proteins were used to monitor the 
functional activity of CXCR4 and CCR5. Antibodies are useful as a tool for biosensor assay 
because their high molecular weight provides a larger response signal in SPR and therefore 
increases the sensitivity of the method.  
 
Materials and Methods: 
The Biacore 3000, Biacore 4000, and Biacore T200 biosensors, CM4 sensor chips, CM4 
Series S sensor chips, and the amine coupling kit were supplied from Biacore AB (Uppsala, 
Sweden).  The MASS-1 biosensor, high capacity amine sensor chips and amine coupling kit 
were obtained from Sierra Sensors (Hamburg, Germany). The 1D4 antibody was purchased 
from the University of British Columbia. The following reagent was obtained through the NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cf2Th-CXCR4 from Dr. Joseph 
Sodroski [13]. The following reagent was obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: Cf2Th synCCR5+ Cells from Dr. Tajib Mirzabekov and Dr. 
Joseph Sodroski [14]. Both receptors were expressed with a C-terminal linear C9 peptide tag 
(TETSQVAPA) specific for the 1D4 antibody. The following reagent was obtained through the 
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Maraviroc (Cat #11580). Lipids 
(synthetic phospholipid blend DOPC:DOPS [7:3, w/w] were purchased from Avanti Polar 
Lipids (Alabaster, AL, USA). Detergents n-dodecyl-b-D-maltoside, n-octyl-b-D-
glucopyranoside, Chaps, n-tridecyl-b-D-maltopyranoside, Big Chap deoxy, DSOL-MK – 
Solution Master Detergent Kit, were purchased from Anatrace (Maumee, OH, USA). 
Cholesteryl hemisuccinate tris salt was purchased from Sigma-Aldrich. Complete, EDTA-free, 
protease inhibitor tablets were purchased from Roche Diagnostics. The It1t compound was 
purchased from Tocris. The 2D7 antibody was purchased from BD Biosciences. The following 
reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
CXCR4 Monoclonal Antibody (12G5) from Dr. James Hoxie [15]. Additional 12G5 antibody 
was purchased from R&D systems.  
 
CCR5 and CXCR4 expression 
Cf2Th/syn CCR5 and Cf2Th-CXCR4 cells were thawed in the water bath at 37 ºC. The thawed 
cells were then transferred to a 50 ml falcon tube and 10 ml of medium was added. The 
medium was composed of 90% Dulbecco’s Modified Eagle Medium (DMEM), 10% Fetal 
Bovine Serum (FBS) supplemented with pen/strep. The cells were spun for 5 minutes at 3000 
rpm at room temperature. The cell pellet was suspended in 5 ml of fresh medium and the 
sample was diluted 1:40 for CCR5 and 1:160 for CXCR4 in T25 flasks containing 8 ml of 
medium and incubated at 37°C until confluent. The cells were then split following release from 
the flask surface by trypsin/EDTA treatment. Prior to trypsinolysis the cells were briefly washed 
with PBS. Once fully recovered, the cells were grown in adherent cell culture and DMEM 
medium supplemented with the antibiotics: 500 μg/ml G418, 500 μg/ml zeocin, 3 μg/ml 
puromycin for CCR5, and 0.4 mg/ml G418 for CXCR4. The cells were harvested, pelleted in 
2x106 and 0.4x106 cell aliquots and frozen at -80 °C until  required.  
 
Preparation of lipids 
Lipids were prepared using a similar procedure to that described previously [9, 11]. Briefly, 
DOPC:DOPS [7:3, w/w] was diluted in chloroform and transferred to glass vials in a volume 
resulting in 5 µMoles in the vial.  The chloroform was evaporated using nitrogen gas thus 
forming a thin layer of lipid on the glass vial. To remove any residual chloroform the samples 
were placed under vacuum for 6-8 hours. The dried lipids were stored at -80 °C until required. 
For preparation of a working solution, the thin lipid layer was solubilised in 1 ml of buffer 
comprised of 50 mM HEPES (pH 7.0), 150 mM NaCl to give a final concentration of 5 mM. 
Four cycles of vortex, freeze, and thaw were performed. The lipids were then stored at 4 °C. 
 
1D4 antibody immobilisation: 
 
For the Biacore 3000, the monoclonal antibody 1D4 was immobilised on a CM4 sensor chip 
using standard amine-coupling chemistry in an assay buffer composed of 10 mM HEPES (pH 
7.4), 150 mM NaCl at 25 ºC. The sensor chip surface was activated using 400 mM 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 100 mM N-hydroxy 
succinimide (NHS) mixed 1:1. The EDC/NHS solution was injected for 10 minutes at a flow 
rate of 10 µl/min. The 1D4 antibody, diluted in 10 mM sodium acetate (pH 5.0), was then 
coupled to the surface using a 15-minute injection at flow rate of 5 µl/min followed by a 7-
minute injection of 1 M ethanolamine (pH 8.5) at flow rate of 10 µl/min to block any remaining 
activated groups on the surface. The antibody density achieved was 8-12000 RU. For antibody 
immobilisation on the Biacore 4000, T200 and MASS-1 the temperature was 30 ºC.  
 
Preparation of Solubilisation Buffers: 
 
The buffers were prepared from 2 M stock solutions of HEPES (pH 7.0), TRIS (pH 7.0), NaCl 
and (NH4)2SO4, 50% glycerol, 50% PEGs 400, 1500, 4000, 6000 and 8000, sucrose  and 
additional salts diluted in purified water to desired concentrations. The pH of the final buffers 
was kept at 7.0. The exact composition of solubilisation buffers is summarised in 
supplementary table 1. 
 
CCR5 and CXCR4 solubilisation buffer screen: 
Cf2Th/syn CCR5 cells (0.4x106) or Cf2Th-CXCR4 cells (2.0x106) were suspended in 180 µL 
of solubilisation buffer containing protease inhibitors. For CCR5, the sample was 
supplemented with 0.5% DDM, 0.5% CHAPS, 0.1% CHS and 0.25 mM DOPC/DOPS (7:3, 
w/w) and for CXCR4, the sample was supplemented with 0.33% DDM, 0.33% CHAPS, 0.07% 
CHS and 0.33 mM DOPC/DOPS (7:3, w/w) to final volume of 200 µL. The cell suspensions 
were briefly sonicated and then incubated on a rocker at 4 ºC.  After 6-8 hours incubation, the 
samples were spun at 14,000 rpm for 20 minutes at 4 ºC. The supernatant was carefully 
transferred to a new vial and used for capture over the immobilised 1D4 antibody surface on 
the Biacore 4000 or Biacore 3000 for the CCR5 or CXCR4 receptors respectively. For the 
Biacore 4000 assays the receptor, solubilised under specific conditions, was captured over 
the antibody surface. Four solubilised receptors can be captured in a single injection step and 
due to the number of spots in each flow cell, samples were captured on both spot 1 and 5 of 
each flow cell, leading to the total of 8 solubilisation conditions monitored per cycle e.g. four 
conditions were captured over spot 1 and four over spot 5, using spot 3 as a reference for 
each flow cell. For the Biacore 3000 the solubilised receptor was captured on three flow cells 
leaving one flow-cell empty as a reference. 
The solubilised receptor was injected for 240 s at flow rate of 5 µL/min. Running buffer was 
injected for 180 s to stabilise and wash the surface, followed by injection of 2D7 (CCR5) or 
12G5 (CXCR4) antibody for 60-180 s (at concentrations of 40 or 50 nM respectively). 
Dissociation was monitored for 120 s. The flow rate was set to 30 µL/min. The surface was 
regenerated with 2 x 10 s-pulses of 10 mM NaOH/ 1% n-octyl-β-D-glucopyranoside solution 
at flow rate of 30 or 50 µL/min followed by a wash with running buffer for 60 s. Control samples 
are receptors solubilised in the previously established solubilisation conditions [11] (20 mM 
TRIS hydrochloride pH 7.0, 100 mM Ammonium sulfate, 10% glycerol and for CXCR4 only 5 
mM MgCl2 and 1 mM CaCl2) and were included in the screen for reference and comparison 
purposes. The control samples were injected at the beginning and end of the screen for the 
CCR5 receptor.  Due to the larger number of samples tested per day on the Biacore 3000 the 
control sample was injected throughout, including the beginning and end of  the CXCR4 
receptor screen. In order to avoid a potential risk of blocking the instrument microfluidics the 
solubilisation conditions were screened in increasing molecular weight of PEGs due to the 
high viscosity of the buffers. 
The running buffer for CCR5 receptor contained 50 mM Hepes (pH 7.0), 150 mM NaCl, 
0.1%:0.1%:0.02% DDM:CHAPS:CHS, 2 mg/ml BSA. For CXCR4 the buffer was additionally 
supplemented with 5 mM MgCl2 and 1 mM CaCl2. The assays were performed at 25 ºC. 
 
CCR5 and CXCR4 Detergent screen: 
Detergents from a Master Solution kit (Anatrace) were plated in 96 well 1 ml plates and then 
aliquoted into 96 well (300 μL) plates. The plates were sealed with thermosealer and stored 
at 4 °C until further use.  
Cells expressing CCR5 or CXCR4 (20 million cells) were suspended in 15 mL of solubilisation 
buffer (CCR5: 20 mM Tris HCl (pH 7.0), 100 mM (NH4)SO4, 10% glycerol; CXCR4: 20 mM 
Tris HCl (pH 7.0), 100 mM (NH4)SO4, 5 mM MgCl2, 1 mM CaCl2 and 10% glycerol) containing 
protease inhibitor and sonicated. For the initial screen 12 µL of a mixture containing lipids and 
detergents at 1:1 ratio were added to each well of a 300 µl 96 well plate. The sonicated cell 
suspension (120 μL) was added to each well. The plates were incubated at 4 ºC for 6 hours 
on the rocker. The samples were spun at 4 ºC at 3,500 rpm for 10 minutes and the supernatant 
was transferred into the assay plate. For the controls 6x106 cells were suspended in 1 ml of 
standard solubilisation buffer containing protease inhibitor and the standard detergent lipid 
mix (CHS/DDM/CHAPS : lipids at 1:1 or 1:2 ratio for CCR5 and CXCR4 receptors respectively) 
and incubated for 2 hours. The screen for CCR5 was performed in 50 mM Hepes (pH 7.4), 
150 mM NaCl, 0.1:0.1:0.02% DDM:CHAPS:CHS, 2 mg/ml BSA 25 ºC. For CXCR4, 5 mM 
MgCl2 and 1 mM CaCl2 was added to the same buffer. The samples were kept at 6 ºC during 
the screen. Each cycle included the capture of receptor followed by injection of a conformation 
dependent antibody (2D7 or 12G5) and regeneration solution 10 mM NaOH/ 1% n-octyl-b-D-
glucopyranoside using the same injection parameters as described above for the solubilisation 
buffer screen.  For the second screen, the same procedure was performed using the detergent 
identified from the first screen by including it in all conditions in a ratio of 1 detergent from 
screen 1: 1 variable detergent:1: lipid (18 µL total volume). Similarly the third detergent screen 
contained a combination of 3 detergents in 1:1:1 ratio (2 known detergents with 1 variable 
detergent, 24 µL total volume including 6 µL of lipids). Injection of the receptor solubilised 
under the standard conditions was included at the beginning, middle and end of the screen as 
a control. Additionally control samples of receptors solubilised using detergents identified in 
screens 1 and 2 were also added. These controls contained blank additions of buffer to mimic 
the dilution factor of the extra detergent used for screen and served as a control for the 
identification of any dilution effect on receptor activity caused by adding the volume of 
detergent to the receptor mixture. The composition of samples and controls is detailed in 
supplementary tables 2 and 3. 
 
Verification of the solubilisation conditions with conformation dependent antibodies. 
Detergents showing the best levels of activities for solubilisation of CCR5 and CXCR4 were 
selected and a series of different ratios of detergent mixtures with lipids were tested for 
correctly folded protein using the conformation dependent antibodies 2D7 and 12G5 as 
probes. Receptors were solubilised and screened using the methods described above. 
Detergent combinations are summarised in supplementary tables 5 and 6. A total of 64 and 
58 combinations were tested for CXCR4 and CCR5, respectively. 
 
Confirmation of active folded protein by small molecule binding:  
For CXCR4, the detergent and buffer screen conditions were tested with the It1t inhibitor. 
CXCR4 was captured on 1D4 sensor surface in running buffer 50 mM Hepes (pH 7.4), 150 
mM NaCl, 0.1:0.1:0.02% DDM:CHAPS:CHS,  5 mM MgCl2, 1 mM CaCl2, 0.5% DMSO at 25 
ºC. It1t was injected at concentrations 0.09 – 200 nM and 3 fold dilutions, at a flow rate of 30 
µL/min, with a 1 min association and up to 5 min dissociation from lowest to highest 
concentrations. For CCR5, Maraviroc was used as a screening compound.  CCR5 was 
captured on 1D4 surface in running buffer 50 mM Hepes (pH 7.4), 150 mM NaCl, 
0.1:0.1:0.02% DDM:CHAPS:CHS,  0.5% DMSO at temperature 25 ºC. Maraviroc was injected 
at concentrations 0.004 – 10 uM and 3 fold dilutions, at a flow rate pf 30 µL/min, with a 1 min 
association and up to 5 min dissociation from lowest to highest concentrations. 
 
Data analysis 
The capture levels (just before 2D7 or 12G5 injection) and antibody binding levels (just after 
the end of 2D7 or 12G5 injection) were collected for the receptors under all conditions and the 
ratio of antibody:capture was calculated. The values of the ratio for each condition were 
normalised for the values of control conditions derived from values for controls injected at the 
beginning, middle and end of the screen for each flow cell separately. We used a trend of 
activity (ratio) decrease specific for each screen. Details of the normalisation procedures are 
shown in Supplementary Figure 1. The capture levels for each condition were normalised for 
the closest control capture level in each screen. For the CCR5 receptor the control sample 
injected at the beginning and end of each cycle exhibited similar activity levels showing that 
the chip was suitable for multiple cycles but also that the receptor is stable over time.  During 
the CXCR4 receptor screen, in which the sample controls were screened at the beginning, 
middle and end, a decline throughout the screen is seen probably due to the regeneration 
cycles and loss of activity of 1D4 antibody surface. Thus, for data analysis, the conditions 
chosen for further analysis were compared to the control samples and the loss of activity was 
taken into consideration. It is important to note that all data for the conformation antibody 
binding level to the captured receptor were normalised for capture levels as well as adjusted 
to levels of controls used during the screens. Normalisation for capture levels consist of 
calculating the ratio between the antibody binding response and the response obtained after 
injection of the solubilised receptor. In this case all the antibody levels are normalised in such 
a way that we estimate the same capture level for each solubilised receptor. This can however 
result in ‘false positives’ where for extremely low captures we can monitor a low level of 
conformation dependent antibody binding, and the resulting ratio will be high. To avoid this, 
we eliminated all conditions with significantly low captures and significantly low antibody 
binding levels (below 20 RU) and resulting data for these conditions were assigned to a zero 
level. All data collected for small molecule binding were normalised for capture levels of 3000 
RU for each receptor for comparability. For data analysis and figure preparation Scrubber 2 
(Biologic software), Sierra Sensors Analyser 2, Microsoft Excel and OriginPRO were used.  
The binding kinetics was fitted using 1:1 binding model using Scrubber 2 software.  
 
 
 
RESULTS: 
Solubilisation buffer screen: 
A collection of 104 solubilisation buffers were tested for CCR5 and CXCR4 receptors’ capture 
and activity levels. Capture levels correspond to ability of each condition to remove the 
receptor from the membrane, whereas the activity levels represent the level of correct folding 
into an active conformation and is measured by binding of conformation dependent antibody. 
These conditions investigate the effects of buffer components, salts, precipitants and polyols 
on the activity of the receptor. The list includes different molecular weights and concentrations 
of PEGs, a high concentration of magnesium sulphate or ammonium sulphate, 2-propanol, 
glycerol or sucrose and different salts covering a range of metal ions. The pH of all buffers 
was kept constant at pH 7.0, the same as the control conditions. The set of buffers was 
designed based on availability from commercial suppliers. These included Reagent 
Formulations from Hampton Research (MembFac HT (HR2-137 Reagent Formulation), 
Crystal Screen (HR2-110 Reagent Formulation) and PEG/Ion Screen (HR2-126 Reagent 
Formulation)). The list of solubilisation buffers used is shown in Supplementary Table 1. 
The folding of the receptors into an active conformation, which we refer to as receptor activity, 
was monitored by the binding of the conformation specific antibodies 2D7 and 12G5 for CCR5 
and CXCR4, respectively. The normalised antibody:capture ratios were plotted against the 
solubilisation buffers conditions. To simplify the presentation of the screen the buffers and 
additives were combined into related groups that served for construction of 3D graphs for the 
solubilisation buffer screen. The graphs are shown in Figure 1 A for CCR5 and B for CXCR4. 
The binding of the antibody to control samples is represented by a plane at response level 1 
with transparent planes above and below representing the standard deviation. Bars showing 
the responses above the control correspond to solubilisation conditions that improve the 
activity of receptors and bars below the control response level representbuffer conditions less 
suitable for maintaining receptor in an active conformation.  A similar approach was used to 
analyse the capture levels for each solubilisation buffer. The resulting 3D plots are shown in 
figure 1 C and D. The following results of the solubilisation buffer screen focuses on the 
influence of the buffer additives separately on each receptor activity (e.g. foldedness into an 
active conformation) and capture levels (absolute amount of receptor captured).   
 
Figure 1. A. Normalised binding levels for the 2D7 antibody binding to the CCR5 receptor solubilised using 102 different 
solubilisation buffer conditions. The light blue plane represents the binding level of 2D7 antibody with standard deviation for CCR5 
solubilised using the standard control condition. B. Normalised binding levels for 12G5 antibody binding to CXCR4 receptor 
solubilised using 102 different solubilisation buffer conditions. The light blue plane represents the binding level of 12G5 antibody 
with standard deviation for CXCR4 solubilised using the standard control condition. The buffers 1-16 and additives 1-12 are 
summarised in the tables. C. Normalised capture levels for the CCR5 receptor solubilised using 102 different solubilisation buffer 
conditions. The light blue plane represents the capture level with standard deviation for CCR5 solubilised using a standard control 
condition. D. The normalised capture levels for CXCR4 receptor solubilised using 102 different solubilisation buffer conditions. 
The light blue plane represents the capture level with standard deviation for CXCR4 solubilised using a standard control condition. 
Buffers 1-16 and additives 1-12 are summarised in the tables.  
 
In the presence of a consistent mix of DDM/CHS/CHAPS/lipids each set of buffers was 
screened utilising either 100 mM NaCl or 100 mM (NH4)2SO4 as the salt.  Substitution of 
ammonium sulphate for NaCl without other additives e.g. buffer 1 compared with buffer 2 etc. 
has little effect on the activity with similar values seen in each corresponding condition 
suggesting that it is the addition of other additives that can have more of an effect. The addition 
of 1 M ammonium sulphate (Additive 2, Fig1 A and B) has slightly more of an effect on the 
activity with CCR5 activity generally slightly lower than the control condition and the activity of 
CXCR4 generally slightly higher, the capture is either a bit higher or close to the control for 
both CXCR4 and CCR5.  In contrast the presence of 2-propanol in solubilisation buffers has 
a negative effect on active folding. Very low or no activity was observed for CXCR4 receptor 
in all the solubilisation buffers tested while for the CCR5 receptor the activity was only about 
50% of the control.  Interestingly, the capture levels were similar for both CCR5 and CXCR4 
receptor at levels 800 – 1200 RU suggesting that while the amount of protein captured and 
thus solubilised is similar the 2-propanol had more of an effect on the folding of CXCR4 into 
an active conformation than CCR5. Magnesium sulphate (additive 4) addition in buffers 1-8 
solubilises CCR5 at activities close to control activity with capture levels that are similar to the 
control. For CXCR4 the same buffers show a higher activity of receptor in the presence of 
magnesium sulphate however the capture levels of CXCR4 relative to the CXCR4 control are 
lower. Generally, the addition of 20% PEG 8000 both lowers activity (foldedness) and also 
capture (solubilisation) for the CCR5 receptor in all the solubilisation buffers tested (buffers 5-
6 and 9-16).  In contrast to the buffers containing metal ions, the presence of ammonium 
sulphate slightly, particularly in the absence of glycerol, increases the activity when compared 
to the other buffers in the presence of 20% PEG 8000.  Interestingly, the condition without 
glycerol has a capture level similar to the control and an activity 78% of the control suggesting 
the combination of PEG8000 with glycerol has a negative effect on both solubilisation and 
obtaining an active conformation.  A similar pattern of low activity is seen when the 
concentration of PEG 8000 is 15%, however for most of the buffers tested at this concentration 
(1-8) the activity is higher than at 20% PEG 8000 and the solubilisation is better thus 
confirming that the PEG 8000 is having a negative effect.  For CXCR4 the pattern is different.  
At a concentration of 20% PEG, in common with CCR5 there is generally low capture, with 
the exception of the buffer containing no glycerol (buffer 16).   Additionally, there is no activity 
apart from buffer 16 (close to control levels) and the phosphate containing buffer 12 (54% of 
the control). At 15% PEG 8000 we observe higher activity in buffers containing ammonium 
sulphate compared to NaCl as well as a dramatic increase in capture levels. The increase of 
PEG 8000 concentration from 15% to 20%, in buffers 5 and 6, significantly reduces activity.  
10% PEG 6000 provides similar good levels of activity and high capture levels for CCR5 with 
either ammonium sulphate or NaCl (buffers 1-8). An increase in PEG 6000 concentration to 
12% coupled with the addition of different metal ions (buffers 9-10 and 12-16), with the 
exception of buffer 11 containing zinc acetate, results in high or very high capture levels 
(solubilisation) but lower activity levels than in buffers 1 to 8.  Buffer 11 (zinc acetate) not only 
has the lowest activity level (53% of the control) but it also displays poor solubilisation 
(capture).  CXCR4 behaves similarly to CCR5 in buffers 1-8 with good activity levels for all 
buffers.  However, buffers 2, 4, 6, 8 and 16 containing ammonium sulphate consistently have 
higher activity levels than the equivalent NaCl containing buffers. With the exception of buffer 
12 containing potassium phosphate, the activity in the presence of 12% PEG 6000 with 
different metal and anions is lower than the control. In particular, very low activity was 
observed for buffer 9 with calcium chloride and no activity for buffer 11 (zinc acetate). Capture 
levels (solubilisation) were generally high except for buffers 9-11 containing calcium, 
magnesium and zinc. 
 Buffers containing 10 or 15 % PEG 4000 generally show good activity and good levels of 
capture for CCR5. The exception is a very low capture level with moderate activity observed 
for zinc acetate containing buffer 11 (15% PEG 4000). For CXCR4 PEG 4000 maintains a 
level of activity similar to the control for buffers 2, 4, 6, 8 and thus are similar to the PEG 6000 
conditions where ammonium sulphate containing buffers are more active than the equivalent 
buffers with NaCl or no salt (buffer 15). Buffers 12, 13, 14 comprising potassium phosphate, 
sodium citrate or lithium sulphate also give high levels of activity and capture.  The absence 
of glycerol (buffer 16) has no effect on activity. This contrasts with the very low captures and 
the low or no activity that were observed for buffers 9-11 containing calcium, magnesium and 
zinc.  
15 % PEG 1500 shows good activity (better than the control in a number of conditions) for 
CCR5 with high capture levels except in buffer 11 containing zinc where the activity is also 
lower. For CXCR4 the activity is high (similar or better than the control) except in buffers 9-11 
and 15 containing calcium, magnesium, zinc and no salt.  The activity of the ammonium 
sulphate containing buffer was consistently higher than equivalent NaCl buffer.  All tested 
buffers showed high capture levels except buffer 11 containing zinc.  
PEG 400 maintains good activity for all tested buffers for both CCR5 and CXCR4. Capture 
levels are higher for CCR5 compared to CXCR4 with the level of capture of CXCR4 
consistently at about 50% of the control.  Despite the lower capture levels for CXCR4, the 
same pattern of higher activity (close to or higher than the control level) seen in 
PEG/ammonium sulphate containing buffers compared with the equivalent PEG/NaCl buffers 
is observed. For CCR5 a number of conditions have a higher activity than the control. 
We did not observe significant difference on receptor activity between equivalent glycerol and 
sucrose conditions, although the majority of screened conditions did show slightly better 
activity in the presence of glycerol. A selection of 32 buffers was also designed to compare 
the presence of Tris or Hepes. Again, although we did not see significant differences in activity 
for CCR5, CXCR4 shows a slight preference for Tris based solubilisation buffers compared to 
Hepes. 
In summary, the activity of CXCR4 was negatively affected by buffers containing calcium 
chloride, magnesium chloride and zinc acetate (buffers 9-11) or isopropanol.   The addition of 
1M magnesium sulphate gave the highest levels of activity with ammonium sulphate having a 
similar positive effect. Buffers containing 15% PEG 400 in combination with 100 mM 
ammonium sulphate or PEG 1500 with potassium phosphate, sodium citrate or lithium 
sulphate also gave levels of activity higher than the control. For CCR5 there was less of a 
dramatic effect however a number of conditions containing either PEG 1500 or PEG 400 result 
in activity levels higher than the control.  Interestingly in the top 20 solubilisation conditions for 
both receptor, seven conditions (Table 1 Supplementary data; 16, 26, 42, 80, 84, 88 and 89) 
overlap for both CCR5 and CXCR4 containing mainly 15% PEG 1500 or 4000 and the 
presence of sulphates. 
 
Solubilisation buffer confirmation of active folding by binding of small molecules 
Twenty solubilisation buffers (2, 4, 10, 11, 12, 16, 19, 26, 27, 42, 50, 51, 68, 72, 80, 84, 88, 
95, 99, 100) were further selected for CCR5 and tested for binding of the slow off-rate small 
molecule maraviroc [16]. For better comparison of the conditions, binding sensorgrams for 
single concentration 370 nM are shown in Figure 2 – data collected on Sierra Sensors MASS-
1 and Biacore T200 instruments. In the graph next to each sensorgram the overlay shows 
binding response at this concentration. All responses were normalised for a capture level of 
3000 RU. The highest response was observed in condition 99 containing ammonium sulphate 
and PEG 1500 (Supplementary Table 1).  
 
 
 
Figure 2: Binding responses for maraviroc injected at 370 nM to CCR5 solubilised at different conditions collected on MASS-1 
(A) and Biacore T200 (B) instruments. Smooth traces correspond to 1:1 kinetic fit. C, D: Comparison of the binding levels for 
each tested solubilisation condition. The response level is read from each sensorgram just after end of the injection. The colours 
of the bars correspond to the colours of sensorgrams, the number on the x axis corresponds to solubilisation buffer ID 
(Supplementary table 1). 
 
Due to the lower number of detected conditions showing a better activity for CXCR4 compared 
with the control, we selected only seven buffer conditions (8, 26, 27, 32, 56, 80 and 88) based 
on 12G5 levels as well as variability of additives in buffer composition and tested these using 
Sierra sensors MASS-1 and Biacore T200 instruments. CXCR4 inhibitor It1t at concentration 
series 0.4 – 200 nM was injected over the surfaces. Sensorgrams are shown in figure 3 (A: 
Data collected using MASS-1, B: data collected using Biacore T200). Buffers 56, 80 and 88 
containing magnesium sulphate, and potassium phosphate and lithium sulphate with addition 
of PEG 1500 showed the best response levels compared to the control solubilisation condition.   
The kinetic parameters are summarised in Table 1.        
 
 
Figure 3. Binding sensorgrams for It1t bound to CXCR4. It1t was injected at concentrations 0.09 to 200 nM. A. the binding to 
CXCR4 receptor solubilised using 6 different solubilisation buffers: control, 26, 27, 56, 80 and 88 was analysed using the MASS-
1 instrument. B. binding to CXCR4 receptor solubilised using 6 different solubilisation buffers: control, 8, 32, 56, 80 and 88 was 
analysed using the Biacore T200. The orange traces represent a 1:1 kinetic fit. The buffer ID composition is summarised in 
Supplementary table 1. 
 
Table 1: Kinetic parameters for It1t compound binding to CXCR4 solubilised using different solubilisation buffers 
and detergents (Solubilisation buffer – Supplementary Table 1, Detergent used for solubilisation, Detergent present 
in the assay buffer, kinetic parameter of binding – ka – on-rate, kd – off-rate and KD – affinity, corresponding figure). 
Instrument Solubilisation 
buffer Detergent in solubilisation 
buffer Detergent in assay buffer ka (M-1s-1) kd (s-1) KD (nM) 
 
Mass-1 
Standard buffer CDC CDC 2.95(±0.08)e6 0.0036(±0.0005) 1.21(±0.04) nM 
Fig.3 
26 CDC CDC 3.08(±0.08)e6 0.0035(±0.0005) 1.13(±0.03) nM 
27 CDC CDC 3.4(±0.1)e6 0.0028(±0.0005) 0.83(±0.03) nM 
56 CDC CDC 2.73(±0.05)e6 0.0030(±0.0003) 1.10(±0.02) nM 
80 CDC CDC 1.56(±0.03)e6 0.0025(±0.0002) 1.58(±0.03) nM 
88 CDC CDC 3.01(±0.07)e6 0.0030(±0.0003) 1.01(±0.03) nM 
T200 
Standard buffer CDC CDC 1.39(±0.02)e6 0.0044 (±0.0004) 3.24(±0.06) nM 
8 CDC CDC 1.39(±0.01)e6 0.0032(±0.0001) 2.28(±0.02)nM 
32 CDC CDC 1.51(±0.02)e6 0.0032(±0.0002) 2.14(±0.02)nM 
56 CDC CDC 1.32(±0.06)e6 0.0043(±0.0001) 3.27(±0.01)nM 
80 CDC CDC 1.69(±0.02)e6 0.0043(±0.0002) 2.53(0.02)nM 
88 CDC CDC 1.64(±0.01)e6 0.0048(±0.0002) 2.95(±0.01)nM 
Standard buffer CDC CDC 9.02(±0.07)e5 0.0033(±0.0001) 3.69(±0.02)nM 
Fig.5 
Standard buffer 58 CDC 9.60(±0. 10)e5 0.0036(±0.0002) 3.69(±0.03)nM 
Standard buffer 59 CDC 1.08(±0.06)e6 0.0038(±0.0001) 3.54(±0.02)nM 
56 59 CDC 1.47(±0.01)e6 0.0048(±0.0002) 3.25(±0.02)nM 
80 59 CDC 1.28(±0.01)e6 0.0045(±0.0002) 3.55(±0.03)nM 
Standard buffer 59 0.1% T323 + 
0.05% B310 1.74(±0.02)e6 0.0050(±0.0002) 2.85(±0.02)nM 
56 59 0.1% T323 + 0.05% B310 1.63(±0.02)e6 0.0052(±0.0003) 3.16(±0.03)nM 
80 59 0.1% T323 + 0.05% B310 1.79(±0.02)e6 0.0056(±0.0003) 3.15(±0.03)nM 
 
 
 
Detergent screens for CCR5 and CXCR4 receptors 
Detergents represent an essential component for both solubilisation and the activity of 
membrane proteins. The importance of selecting correct detergents was reported previously 
[9, 11]. We used the Biacore 4000 and 3000 instruments to screen 99 different detergents for 
receptor solubilisation and a total of over 300 mixtures of the detergents to determine which 
combinations can improve or maintain receptor activity for binding of the conformation 
dependent antibodies 12G5 and 2D7. We found both CCR5 and CXCR4 receptors prefer 
different detergents for maximal activity but also can maintain activity using the same 
detergents. The detergent mixtures were identified by systematic screen of series of 99 
detergents followed by mixing the best detergent with the remaining detergents for follow up 
screens as described previously [17]. In the first detergent screen we found the best 
solubilisation conditions for CCR5 were with using MNG, then maltosides, CHAPS/CHAPSO, 
cymal-4, GDN and sucrose monododecanoate (Figure 4A,C; Supplementary data Table 3). 
For the second screen MNG detergent was mixed with each of the rest of detergents in a ratio 
1:1. Again, solubilisation conditions having GDN, several maltosides and sucrose 
monododecanoate showed high responses for conformation dependent antibody. 
Interestingly, some conditions such as anapoe detergents, that showed minimal or no binding 
in the first screen, showed high responses. This can be caused by complementing the 
efficiency of the second detergent used in the mixture. The third screen contained mixtures of 
MNG+GDN in all detergent conditions. PMAL-C8 showed highest response in combination 
with MNG and GDN followed by tetradecyl-B-D-maltoside. Several maltosides and also 
sucrose monododecanoate showed high responses in this detergent mixture. 
 The first detergent screen for CXCR4 receptor showed highest responses for MNG and 
tridecyl-b-D-maltoside. Several other maltosides, cymal-4, sucrose monododecanoate, 
Chaps, Chapso and Big CHAP deoxy also solubilised CXCR4 receptor at high activities. For 
the second screen tridecyl-b-D-maltoside was added to mixtures of all detergents. Highest 
responses were observed for mixtures containing Big CHAP and Big CHAP deoxy. The third 
screen contained the mixture of screening detergents with tridecyl-b-D-maltoside and Big 
CHAP. The highest response with this mixture was in the presence of GDN, however the 
response was lower compared to mixture of just two detergents from previous screen (tridecyl-
b-D-maltoside and Big CHAP). Capture levels for each detergent mixture are shown in 
Supplementary Table 2 and Figure 4 B, D. Interestingly, the highest capture levels show low 
or no binding to the conformation dependent antibody. Capture levels can provide an 
indication of efficacy of the solubilisation condition for the receptor but do not indicate how 
active the receptor is. Indeed the highest receptor activity was observed for conditions where 
CXCR4 was captured at intermediate levels comparable with control (~500-800 RU). It is likely 
that the low activity of CXCR4 captured at high levels is caused by CXCR4 forming aggregates 
and capturing non-specifically to the surface. However, low capture levels do suggest low a 
solubilisation efficiency that is not suitable for extraction of receptor from the membrane.  For 
CCR5 the normalised intermediate capture levels for the active receptor were at higher levels 
compared to CXCR4 1500-2000 RU. Supplementary Table 4 summarises detergents showing 
top 10 highest activity levels for both CCR5 and CXCR4. We found approximately 70% overlap 
of detergents suitable for both receptors. MNG detergent that is a common detergent used for 
GPCRs purification and assays was suitable for both receptors. Additionally, we found n-
dodecyl-B-D-thiomaltoside provided very good activity for both receptors (ratios for CXCR4 = 
0.93 and CCR5 0.63) and was found more suitable than n-dodecyl beta maltoside (DDM; 
(ratios for CXCR4 = 0.84 and CCR5 0.61) commonly used for GPCR preparations. 
Verification of detergent mixtures with conformation dependent antibodies: 
To further confirm which detergent mixtures improve the activity of CXCR4, we selected 3 
detergents: tridecyl-β-D maltoside, Big CHAP and MNG and prepared various mixtures of the 
detergents with lipids for screening of the CXCR4 activity. Supplementary data Table 6 and 
Figure 4F summarises the concentrations of each detergent in mixture and the activity in each 
mixture. It is interesting to see that various combinations of detergents and lipids at different 
concentrations can significantly influence activity of solubilised receptor. We found the 
combination of MNG and lipids (ranking condition 58, 57, 56 and 52) and T323, B310 and 
lipids (condition 59) showed the best results (ratio values 1.20-1.33). Generally, the presence 
of lipids slightly increases the activity of the receptor and increasing detergent concentration 
has negative effect on receptor activity. For CCR5 we selected MNG, GDN, n-tetradecyl-β-D-
maltoside (T315) and Anapoe-35 detergents in mixtures with lipids. None of the tested 
detergent mixtures showed activity above the control and therefore were not pursued further 
(Supplementary data Table 5 and Figure 4E). The highest activity was seen with combinations 
of detergents MNG, Anapoe, GDN and lipids. Higher detergent concentrations also 
significantly decreased receptor activity. 
 
 
Figure 4. A. Normalised binding level responses for 2D7 antibody binding to CCR5 solubilised using different detergent conditions 
for screens 1-3. The light blue plane represents the binding level of the 2D7 antibody with standard deviation for CCR5 solubilised 
using a standard control condition. B. Normalised binding level responses for 12G5 antibody binding to CXCR4 solubilised using 
different detergent conditions for screens 1-3. The light blue plane represents the binding level of the 12G5 antibody with standard 
deviation for CXCR4 solubilised using a standard control condition. C. Normalised capture levels for CCR5 receptor solubilised 
using different detergent conditions. The light blue plane represents the capture level with standard deviation for CCR5 solubilised 
using a standard control condition. D. Normalised capture levels for the CXCR4 receptor solubilised using different solubilisation 
detergent conditions. The light blue plane represents capture level with standard deviation for CXCR4 solubilised under a 
standard control condition. E. Normalised binding level responses for the 2D7 antibody binding to CCR5 solubilised in different 
detergent/lipid mixtures and capture levels.  The light blue plane represents binding level of 2D7 antibody with standard deviation 
for CCR5 solubilised using the standard control condition. F. Normalised binding level responses for the 12G5 antibody binding 
to CXCR4 solubilised in different detergent/lipid mixtures and capture levels. The light blue plane represents binding level of 
12G5 antibody with standard deviation for CXCR4 solubilised using the standard control condition 
Verification of detergent solubilised protein with small molecules: 
To further determine the effect of detergents on activity of solubilised receptors we measured 
binding of small molecules It1t and maraviroc to CXCR4 and CCR5 receptors respectively, 
using the detergent conditions that showed highest binding responses to the conformation 
dependent antibodies. For CXCR4 we compared detergent mixtures 58 (MNG) and 59 (T323, 
B310) (Figure 5 A-H, Supplementary table 6). We found detergent 59 slightly improved binding 
activity of the receptor over the control and this improvement was enhanced by adding this 
detergent mixture into the assay buffer. Solubilisation condition 58 showed lower response for 
compound binding compared to the control. For CCR5 we tested detergent mixtures 15 (MNG 
and GDN) and 34 (MNG) as these detergents were selected for the main detergent screen as 
well as ranked high in the confirmation screen. We found the control showed best binding 
affinity. Interestingly the binding in condition 15 could be improved by replacing the standard 
detergent in the assay buffer with 0.01% MNG – which is one component of the detergent 
mixture used for solubilisation (Figure 5 I).  Condition 58 for CXCR4 and 34 for CCR5 are 
identical, interestingly both these conditions decrease the activity for both receptors to ~ 50% 
compared to control even though the conformation antibody binding is amongst the best 
compared to other tested detergent mixtures.  
 
Figure 5. A-H. Binding sensorgrams for It1t bound to CXCR4. It1t injected at concentrations 0.09 to 200 nM binding to CXCR4 
receptor solubilised using different detergent mixtures (supplementary table 6) and solubilisation buffers (supplementary table 1). 
A. Control solubilisation condition, B. CXCR4 solubilised using mixture 58 and standard solubilisation buffer. C. CXCR4 
solubilised using mixture 59 and standard solubilisation buffer. D. CXCR4 solubilised using detergent mixture 59 and solubilisation 
buffer 56. E. CXCR4 solubilised using detergent mixture 59 and solubilisation buffer 80. F. CXCR4 solubilised using detergent 
mixture 59, standard solubilisation buffer and assay buffer containing detergent mixture 0.1% T323 + 0.05% B310. G. CXCR4 
solubilised using detergent mixture 59, solubilisation buffer 56 and assay buffer containing detergent mixture 0.1% T323 + 0.05% 
B310. H. CXCR4 solubilised using detergent mixture 59, solubilisation buffer 80 and assay buffer containing detergent mixture 
0.1% T323 + 0.05% B310. I. Binding sensorgrams for maraviroc injected at 370 nM to CCR5 solubilised using different detergent 
combinations (supplementary table 5). Black-CCR5 control (solubilisation-CDC (CHS/DDM/CHAPS), assay buffer – CDC), green 
(solubilisation-15, assay buffer – MNG), blue (solubilisation-15, assay buffer – CDC), red (solubilisation-34, assay buffer – CDC), 
orange (solubilisation-34, assay buffer – 0.01% MNG) 
 
 
Comparison of Screening Instruments 
The application of several SPR platforms for screening and verifying solubilisation conditions 
improved the assay throughput and also enabled a comparison of these platforms. The 
general approach was the same for all the instruments, where the 1D4 antibody was 
immobilised over all flow cells (and spots with respect to Biacore 4000 experiments) and the 
solubilised samples were captured via the C9 tag followed by conformational antibody injection 
and finally regeneration of the antibody surface enabling the performance of the next cycle 
using the same antibody surface. Using the Biacore 4000 which is capable of processing 4 
samples simultaneously and having 5 detection spots, meant that the methods benefited from 
higher throughput and more samples could be processed per cycle.  
When using the Biacore 3000 one sample is processed per injection. It was possible to capture 
three solubilised receptors per cycle. Solubilised receptor was captured over flow cell 1, 3 and 
4, leaving flow cell 2 as a reference flow cell. The rest of the injections were the same as the 
Biacore 4000 experiment. In the setup for the Biacore 3000 the methods were longer and also 
the number of the regeneration cycles increased for each run thus a lower number of samples 
could be processed per cycle. Although, one sensor chip was sufficient for the study of ~ 100 
solubilisation conditions on the Biacore 4000, on the Biacore 3000 two sensor chips were 
needed for the screening as the antibody surface lost activity after multiple regeneration 
cycles. However, the buffer and reagent consumption was significantly lower on Biacore 3000 
compared to the Biacore 4000. Thus, the major difference is the choice between a time- or 
cost-efficient platforms. 
The Sierra Sensors MASS-1 instrument benefits from the simultaneous processing of 8 
samples in one injection where samples are addressed over 8 separate channels containing 
one reference and one target spot. The advantage of this instrument is in its ability to rapidly 
screen a large variety of solubilisation conditions while providing reasonable sensitivity for 
small molecule binding. We used this technology to confirm selected solubilisation buffer 
conditions for CXCR4 and CCR5 receptors using small molecules It1t and Maraviroc 
respectively injected at 8 concentrations each. One sensor chip was suitable to test up to 24 
conditions within 3 days (compared to 3 conditions/day using Biacore T200) providing a time-
effective approach to confirmation of the solubilisation buffers.  
The MASS-1 instrument data quality was comparable to Biacore T200. Both data collected for 
CXCR4 and CCR5 on the Biacore T200 and Sierra MASS-1 instrument were at low level of 
response units however the kinetic and affinity values collected on both instruments were in 
the same range for all screened solubilisation conditions.  
When using different instruments for the assays it is important to include controls within each 
screen to maintain comparability of the results. For example as seen in Fig. 2 C and D the 
ranking of solubilisation buffer conditions for CCR5 receptor interaction with maraviroc is very 
similar for both instruments. Although the condition 19 shows higher response compared to 
condition 2 in dataset collected on Mass-1 instrument compared to data obtained from T200 
instrument, this was the only discrepancy found. However condition 19 did not provide the 
best solubilisation activity for binding of small molecule maraviroc from the conditions selected 
for confirmations. The best solubilisation buffer (condition 99) was identified by both 
instruments independently suggesting reasonable good comparability of assays collected with 
both technologies. 
 
Discussion 
In this study we used surface plasmon resonance technology to screen solubilisation 
conditions for two GPCRs: CXCR4 and CCR5. Both receptors belong to the chemokine family 
and are both involved in HIV virus entry into host cells. However, these receptors share only 
30.4% identity suggesting the results from the solubilisation screens can provide information 
on the transferability of the solubilisation conditions between a wider varieties of GPCRs.  
These screens in this paper followed on studies published previously [11, 12, 17] however at 
a larger scale. A total of 950 different solubilisation conditions containing various buffer 
components and detergent/lipid mixtures were explored to monitor which of these conditions 
can solubilise each receptor in an active conformation and determine the similarities and 
differences between the solubilisation of the two receptors. We also compared the strengths 
of each solubilisation condition by monitoring the capture levels of each receptor. Interestingly 
we found some conditions that were influencing receptor activity similarly for both GPCRs, but 
also some conditions had an opposite effect. We observed that conditions with high 
solubilisation strengths – resulting in high capture levels do not always solubilise the receptor 
in an active conformation. Extremely high capture levels, well above the levels for controls, 
may be caused by aggregation of the receptor in a specific detergent and/or non-specific 
binding to the sensor surface. Very low capture levels can provide high activity levels relative 
to the capture level but in this case the sensitivity of the assay can then also significantly 
decrease. We were also able to examine the correlation with these data on active folding 
obtained by binding of a high molecular weight antibody in a high-throughput screen to a 
smaller low through-put verification screen using small molecules as probes of receptor 
activity. Interestingly we found that even though some solubilisation conditions showed high 
levels of binding to the receptor for the conformation-dependent antibody the ranking of these 
conditions did not translate fully to an activity-based ranking for small molecule binding. For 
example, for CCR5 receptor the best solubilisation buffer condition was found to be condition 
2 containing 15% PEG 400 (Supplementary table 1) based on a conformation-dependent 
antibody response level, however this condition ranked 4th from data collected for binding of 
maraviroc.  Maraviroc bound best in condition 99 containing 15% PEG 1500 which ranked 17th 
based on antibody response level.  For CXCR4 receptor the correlation was better, for 
example the best response to 12G5 antibody to CXCR4 was found for receptor solubilised in 
buffer condition 56 containing Magnesium and 10% sucrose, which ranked 2nd for It1t binding 
response level. The best condition based on It1t binding was found to be condition 80 
containing potassium and 15% PEG 1500 which ranked 4th for binding of antibody. Similar 
observations were recorded for detergent screens. Discrepancies between these two types of 
assays may be mainly caused by the assays monitoring different binding sites and also the 
binding mechanism for both antibody and small molecules. The ranking based on antibody 
binding serves mainly to distinguish between ‘good’ and ‘bad’ solubilisation conditions and are 
useful mainly due to their large molecular weight and therefore larger signal enabling these 
assays to be run in a high through-put mode. In order to obtain a higher degree of accuracy 
when comparing the best conditions identified by antibody screens, verification with small 
molecules is also necessary.  
Conclusion 
By using the high through-put solubilisation condition screens for the two receptors CXCR4 
and CCR5 we have determined buffer and detergent components that can keep the receptors 
in an active form. Using the minimum activity threshold at 0.9 we found at least 51 buffer 
conditions for CCR5 receptor and 46 buffer conditions for CXCR4 receptor that can be used 
for solubilisations without any significant loss of activity. 32 conditions were amongst best 
conditions for both receptors suggesting ~30% overlap of tested solubilisation buffers 
(supplementary table 7). We also found 58 detergent combinations for CCR5 and 77 detergent 
combinations for CXCR4 that can maintain receptor activity above level of 0.9.  These data 
can provide important indicators for optimising an activity assay for example CXCR4 prefers 
ammonium sulphate rather NaCl as a salt in the solubilisation buffer.  Moreover, the selection 
of different solubilisation buffers and detergents is important for alternative methods to study 
membrane proteins that can be used in addition to or instead of SPR, such as X-ray 
crystallography, biochemical assays, radio-ligand assays, small molecule and fragment 
screens. Not all detergents and buffer components are compatible with such assays and thus 
having flexibility in the selection from which buffers or detergent can be chosen is 
advantageous. 
By testing the two receptors we could see that despite being members of the same family 
there were both some similarities and differences in their preference for different conditions.  
While for these proteins that had known solubilisation conditions to produce active proteins 
we achieved modest increases in active solubilisation.  These data do suggest the starting 
point for determination of a solubilisation buffer composition for an unknown protein and the 
variables worth testing such as type of salt, the addition of a low molecular weight PEG in 
order to optimise purification of active protein as well as the combination of detergents.   We 
show an important parameter is the detergent that is selected for mixtures, in particular a 
detergent which looks unpromising on its own can in combination with another detergent 
confer good solubilisation and activity. Thus, ideally a matrix that screens mixtures of 
detergents should be used to fully determine the ideal conditions for the receptors of interest. 
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